Related Experiment Videos
Inhibition of rat mammary carcinogenesis by an arotinoid without a polar end group (Ro 15-0778)
1Pharmaceutical Research Department, F. Hoffmann-La Roche & Co. Ltd., Basel, Switzerland.
Abstract:
The influence of an arotinoid without a polar end group (Ro 15-0778) on rat mammary carcinogenesis was investigated. Mammary tumors were induced by oral administration of 15 mg, 7,12-dimethylbenz-(a) anthracene (DMBA) to 50-day-old female Sprague-Dawley rats. Ro 15-0778 inhibited the development of mammary adenocarcinomas. The percentage of tumor-bearing rats, the mean number of tumors per rat as well as the mean total volume of tumors per rat were dose-dependently reduced by Ro 15-0778. The results are of particular interest, since this compound--probably because of the lack of a polar end group--does not induce the signs and symptoms of hypervitaminosis A. The inhibition of mammary cancer development by Ro 15-0778 compares favorably with that of N-(4-hydroxyphenyl) retinamide the hitherto most effective retinoid for prevention of chemically-induced mammary cancers in rats.
Insights
A novel arotinoid, Ro 15-0778, effectively inhibited rat mammary carcinogenesis without causing hypervitaminosis A. This compound shows promise for preventing chemically-induced mammary cancers.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Retinoids are crucial in cell differentiation and proliferation.
- Chemically-induced rat mammary carcinogenesis is a model for human breast cancer.
- Arotinoids, a class of retinoids, are being investigated for cancer chemoprevention.
Purpose of the Study:
- To investigate the efficacy of arotinoid Ro 15-0778 in preventing mammary carcinogenesis in rats.
- To assess the safety profile of Ro 15-0778, specifically its lack of hypervitaminosis A symptoms.
- To compare the efficacy of Ro 15-0778 with other known retinoids in mammary cancer prevention.
Main Methods:
- Female Sprague-Dawley rats were administered 7,12-dimethylbenz-(a) anthracene (DMBA) to induce mammary tumors.
- Rats were treated with varying doses of arotinoid Ro 15-0778.
- Tumor incidence, multiplicity, and volume were measured and analyzed.
Main Results:
- Ro 15-0778 significantly inhibited the development of mammary adenocarcinomas in a dose-dependent manner.
- The percentage of tumor-bearing rats, mean tumor number, and mean tumor volume were reduced by Ro 15-0778.
- Ro 15-0778 did not induce signs of hypervitaminosis A, unlike some other retinoids.
Conclusions:
- Arotinoid Ro 15-0778 is a potent inhibitor of chemically-induced mammary carcinogenesis in rats.
- Its lack of polar end group may contribute to its favorable safety profile (no hypervitaminosis A).
- Ro 15-0778 demonstrates comparable or superior efficacy to N-(4-hydroxyphenyl) retinamide for mammary cancer prevention.